News
Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform
In Vivo Biologics Design
Transforming protein therapeutics discovery with high-throughput
in vivo measurement
Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute.
mDesign™ Platform
With our mCodes™ technology, we've unlocked protein multiplexing for pooled in vivo testing of complex biologics.
Our Platform.svg)
Advancing Therapeutic Possibilities
Discover how our innovative platform unlocks the next generation of complex biologics across a range of therapeutic areas.
Learn MoreStay up to date
See All
Blog
In Vivo Biologics Design for Next-Generation Targeting
News
Manifold Bio’s molecular ‘barcodes’ could break through pharma’s in vivo bottleneck